Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis) - Top-Institutions - MDSpire

Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis)

  • By

  • Luciano Ibba

  • Sara Di Giulio

  • Piergiorgio Malagoli

  • Anna Balato

  • Angelo Valerio Marzano

  • Matteo Megna

  • Diego Orsini

  • Lidia Sacchelli

  • Santo Raffaele Mercuri

  • Emanuele Trovato

  • Serena Giacalone

  • Alexia Pedron

  • Marzia Caproni

  • Edoardo Cammarata

  • Aldo Cuccia

  • Andrea Altomare

  • Alexandra M. G. Brunasso

  • Valentina Dini

  • Simone Ribero

  • Nicola Zerbinati

  • Francesco Messina

  • Stefano Caccavale

  • Carlo G. Carrera

  • Luca Potestio

  • Viviana Lora

  • Andrea Carugno

  • Federico Bardazzi

  • Giovanni Paolino

  • Antonio Costanzo

  • Alessandra Narcisi

  • Mario Valenti

  • March 16, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Trials

  • #2

    Massachusetts General Hospital (MGH) Dermatology
    Massachusetts General Hospital (MGH) Dermatology

    Boston, MA

    Key Differentiators

    • Dermatology
    • Clinical Research
    • Immunodermatology

  • #3

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Dermatology
    • Inflammation Research
    • Clinical Trials

  • #4

    University of Michigan Dermatology
    University of Michigan Dermatology

    Ann Arbor, MI

    Key Differentiators

    • Dermatology
    • Psoriasis Research
    • Clinical Trials

  • #5

    National Psoriasis Foundation Research Center
    National Psoriasis Foundation Research Center

    Portland, OR

    Key Differentiators

    • Psoriasis Research
    • Patient Advocacy
    • Clinical Studies

Original Source(s)

Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis)

  • by Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, Anna Balato, Angelo Valerio Marzano, Matteo Megna, Diego Orsini, Lidia Sacchelli, Santo Raffaele Mercuri, Emanuele Trovato, Serena Giacalone, Alexia Pedron, Marzia Caproni, Edoardo Cammarata, Aldo Cuccia, Andrea Altomare, Alexandra M. G. Brunasso, Valentina Dini, Simone Ribero, Nicola Zerbinati, Francesco Messina, Stefano Caccavale, Carlo G. Carrera, Luca Potestio, Viviana Lora, Andrea Carugno, Federico Bardazzi, Giovanni Paolino, Antonio Costanzo, Alessandra Narcisi, Mario Valenti

  • March 16, 2026

Related Content

Inhibition of TYK2 in Skin Autoimmune Disorders: Achieving Remission of Discoid Lupus and Psoriasis with Deucravacitinib and Complementary Confocal Microscopy Evidence

Efficacy of AVT04, a Biosimilar to Ustekinumab, in Managing Plaque Psoriasis: Findings from a 28-Week Real-World Study

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial